Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $1,742,812.50 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 31,250 shares of the firm’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $55.77, for a total transaction of $1,742,812.50. Following the completion of the transaction, the insider now directly owns 170,237 shares in the company, valued at $9,494,117.49. This trade represents a 15.51 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Timothy Rolph also recently made the following trade(s):

• On Tuesday, December 10th, Timothy Rolph sold 4,818 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.91, for a total transaction of $148,924.38.

Akero Therapeutics Price Performance

AKRO stock opened at $54.08 on Friday. The stock has a market cap of $3.77 billion, a price-to-earnings ratio of -14.42 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The company has a 50 day simple moving average of $30.26 and a 200 day simple moving average of $28.88. Akero Therapeutics, Inc. has a 1 year low of $15.32 and a 1 year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Bank of America raised shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $35.00 to $63.00 in a research note on Thursday. UBS Group lifted their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research note on Friday. Canaccord Genuity Group lifted their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research note on Tuesday. HC Wainwright lifted their price target on shares of Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Finally, Citigroup lifted their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $75.86.

Hedge Funds Weigh In On Akero Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its stake in Akero Therapeutics by 54.4% in the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock valued at $226,554,000 after purchasing an additional 2,782,029 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Akero Therapeutics by 2.9% during the third quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock valued at $203,053,000 after acquiring an additional 201,225 shares during the last quarter. RTW Investments LP raised its stake in shares of Akero Therapeutics by 9.0% during the third quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock valued at $169,829,000 after acquiring an additional 487,450 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Akero Therapeutics in the third quarter worth $37,392,000. Finally, SG Americas Securities LLC increased its holdings in Akero Therapeutics by 4,022.1% in the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock valued at $16,636,000 after purchasing an additional 583,486 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.